Неходжкинские лимфомы у пожилых (клинико-иммунологические характеристики)
Диссертация
Всестороннее изучение больных в возрасте старше 60 лет показывает, что это достаточно неоднородная группа и больные значительно различаются по физическому, психическому и интеллектуальному статусу. Возрастные изменения индивидуальны. Все вышеперечисленное не имеет четкой связи с хронологическим возрастом, а соответственно при выборе тактики лечения более актуален биологический возраст, точно… Читать ещё >
Список литературы
- Бабичева Л.Г. Значение прогностических факторов при лечении больных диффузной крупноклеточной В-клеточной лимфомой антрациклинсодержащими режимами химиотерапии. Диссертация на соискание ученой степени кандидата медицинских наук. 2005 г.
- Бесова Н.С. Возможности химиотерапии у пожилых больных. Журн. Трудный пациент. Онкология. 2006 № 11
- Волкова М.А., Поддубная И. В. Заведос (идарубицин) в лечении гемобластозов. М 2002: стр 72−82.
- Давыдов М.И., Аксель Е. М. Злокачественные образования в России и странах СНГ в 2007 году. М., 2009
- Давыдов М.И., Демидов Л. В. Основы современной онкологии. М -2002г: стр 170−82.
- Дильман В.М., Михельсон В. М., Наследственная предрасположенность к раку у человека. Общая онкология: руководство для врачей / Под ред. Н. П. Напалкова. Л:. Медицина. 1989.С.143−156. (1)
- Круглова Г. В., Финогенова И. А. // Новое в онкологии. Сборник научных трудов // 2-ой выпуск, Воронеж, 1997, 6−11.
- Левченко К.Ф. Особенности факторов риска развития первично-множественного базально-клеточного рака кожи// Вестник РГМУ. 2007. № 2 С. 23
- Москаленко О.А., Поддубная И. В. Османов Д.Ш. и др. Первичные MALT-лимфомы желудка у больных пожилого возраста. Современная онкология. 2001. Т. 3, № 4. С. 146−151.
- Новые подходы к терапии неходжкинских лимфом. Заведос (идарубицин), под редакцией Ф. Кабаннилас, JI. Линч. М 1998- стр 26.
- Пасечник Д. Г. Непомнящая Е.М. Первично-множественные опухоли с поражением почек // Вопросы онкологии. 2003. Т. 49. № 1 С. 116−118.
- Первично-множественные злокачественные опухоли: Руководство для врачей / Под ред. В. И. Чиссова, А. Х. Трахтенберга. М.: Медицина, 2000. С. 7.
- Поддубная И. В., Москаленко О. А., Балакирева Ю. Н. Неходжкинские лимфомы маргинальной зоны. Современная онкология 2006. Т.8 № 1 С.8- 13.
- Поддубная И.В. Неходжкинские лимфомы. Клиническая онкогематология под ред. Волковой М. А. М — 2007- гл 35: стр 724−770.
- Поддубная И.В. Неходжкинские лимфомы. Клиническая онкогематология под ред. Волковой М. А. М — 2001- гл. 23: стр. 336−375
- Поддубная И.В. Обоснование лечебной тактики при неходжкинских лимфомах. Современная онкология / 2002- № 1- том 4 онкологической энциклопедии: стр 3−7.
- Поддубная И.В., Османов Д. Ш., Курильников, А .Я. Мабтера в терапии неходжкинских лимфом высокой степени злокачественности: схема R-СНОР. Современная онкология, экстра-выпуск по материалам журнала за 1999−2002гг. 2003- стр 13.
- Птушкин В.В. Особенности лечения агрессивных НХЛ у пожилых пациентов. Современная онкология, экстра-выпуск по материалам журнала за 1999−2002. 2003: стр 5−6.
- Справочник по онкологии. Под ред. Н. Н. Трапезникова, И. В. Поддубной. М. Медицина, 1996. С. 150−152.
- Тупицын Н.Н. и др. Экстравыпуск / Современная онкология. 2002. С. 412.
- Aapro MS. Using Cytotoxic Chemotherapy Agents in the Elderly. AS CO, Educational Book, 1999:341−345.
- Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Nature403(6769), 503−511 (2000),
- Anderson T, Chabner BA, Young RC et al. Malignant lymphoma. I. The histology and staging of 473 patients at the National Cancer Institute. Cancer 1982- 50: 2699−2707.
- Anderson Т., Bender R.A., Fisher R.I. et al. // Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term follow-up. // Cancer Treat. Rep., 1977,61, 1057−1066.
- Anon. // A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The non-Hodgkin's lymphoma Classification Project. //Blood, 1997, 89, 3909−3918.
- Ansell S. M., Falkson G., van der Merwe R., Uys A. Chronological age is multifactorial prognostic variable in patients with non-Hodgkin's lymphoma. Ann. Oncol. -1992- 3: 45−50.,
- Aosaza K., Ohsawa M., Soma T. et al. // J. clin. Oncol. 1990 — Vol. 20. -P. 380.
- A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N.Engl. J. Med.-1993- 329: 987.
- Armitage J.O., Potter JF. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age. J Am Geriatr Soc. 1984- Apr- 32(4):269−73.
- Armitege J.O. Weisenburger D.D.J. // Clin. Oncol.J.- 1998-Vol. 16 P.-2780−2795
- Aviles A., Duque G. Leukemia and Lymphoma, 1996- 20(5−6): 495−499., 10 260
- Balducci L. The geriartric patientrequal benefit from equal treatment // Cancer Control. 2001- 8(2s):l-25.
- Balducci L, Extrmann M. Management of cancer in older person: practical approach // One. 2000- 5(3):224−237.
- Balducci L. Management of cancer in the elderly. Oncology (Willinston Park). 2006 Feb-20(2): 135−143
- Balducci L, Parker M., Sexton W., et al. Pharmacology of antineoplastic agent in the elderly patient. Semin Oncol 1989- 16:76−84-
- Berger F., Felman P., Thieblemant C., et al. // Blood. 2000 — Vol. 95.- P. -1950−1956.
- Bernard S.M., Cartwright R.A., Bird C.C., et al. Leuk Res 1984- 8: 681.
- Bloom K., Bini R., Williams C., et al // Cancer 1978.- Vol. 41.- P.1265
- Bonadonna G, Rossi A, Valagussa P. Adjuvant CMF chemotherapy in operable breast cancer: ten years later Lancet. 1985 Apr 27-l (8435):976−7.
- Cameron D.A., Leonard R.C., Prescott R.J. // Identification of prognostic groups in follicular lymphoma. // Leuk. Lymphoma, 1993, 10, 89.
- Carbone A, Tirelli U, Volpe R, et al. Non-Hodgkin's lymphoma in the elderly. A retrospective clinicopathologic study of 50 patients. Cancer 1986−57:2185−9.
- Carbone A, Volpe R, Gloghini A, et al. Non-Hodgkin's lymphoma in the elderly. I. Pathologic features at presentation. Cancer 1990−66:1991−4).
- Case D.C. // Comparison of M-2 protocol with COP in patients with nodular lymphoma.//Oncology, 1984, 41, 159−163
- Cavalli F. Proc. ASCO, 1995, abs. 714
- Coiffier В., Berger F., Giles F. // Follicular lymphomas: morphology, prognostic factors and treatment. The monograph. // Schering-Plough International, 1994.
- Coiffier B, Lepage E, Brier J, Ilerbrecht R, Tilly H, Bouabdallan R, Morel P, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. New Engl J Med 2002- 346(4):235−42.
- Coffier B, Neidbardt-Berard EM, Tilly H. et al Ann. Oncol 1999- 10:1191
- Coiffier B. NHL in the Elderly The Lymphomas. 526−535
- Chrischilles E, Delgado DJ, Stolshek BS, et al. Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma. Cancer Control 2002−9:203−11
- Coltman CA, Dahlberg S, Jones SE, Miller TP, Dana BW, McLekvey EM et al. CHOP is curative in thirty percent of patients with diffuse large cell lymphoma: A twelve year Southwest Oncology Group follow-up. Proc Am Soc Clin Oncol 1986- 5: 197
- Crivellari D., Bonetti M., Castiglione-Gertsch M. et al. J. J. clin. Oncol. -2000−18- 1412−22.
- Czusman M.S., Grillo-Lopez A.J. et al. // Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not outcomein patients treated with rituximab // leuk. Lymphoma, 2006, 47(9), 18 301 840.
- Dana B.W., Dahlberg S., Nathwani B.N., et al. // Long term follow-up of patientis with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. // J. Clin. Oncol., 1993- 11- 644−651.
- Davis ТА. Blood 94 (Suppl.l):88 part 1, nov. 1999
- Dees E.C. O’Reilly S., Goodman S.N. et al.// A prospective pharmacologice valuation of age-related toxicity of adjuvantchemoterapy in women with brest cancer// Cancer Invest 2000- 18- 521 — 9
- Diette K.M., Caro W.A., Roenigk H.H. J. Am. Acad. Dermatol., 1984- 10:896
- Doglioni C. Woterspoon A.S., Moscini A. et al.// High incidence of primary gastric lymphoma in northeasterm Italy. // Lancet. — 1992. Vol. 339. — P. 834−835.
- Durnas C., Loi СМ., and Cusack BJ. Hepatic drug metabolism and aging. Clin Pharmacokinet 1990−19:359−80
- Ezdinli E.Z., Anderson J.R., Melvin F. et al. // Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma. // J. Clin. Oncol., 1985, 3, 769−775.
- Effect of age on the characteristics and clinical behavior of Non-Hodgkin's Lymphoma patients. The non-Hodgkin's Lymphoma Classification Project. J. Ann. Oncol. 1997- 8: 973.
- Elias L. Differences in age and sex distributions amond patients with non-Hodgkin's Lymphoma. Cancer. 1979- 43: 2540.
- Feugier P, Van Hoof A, Sebban С et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin. Oncol. 23. (18), 4117−4126 (2005).
- Fiorentino M.V. Lymphomas in elderly/Leukemia 1991- 5(suppl 1):79 -85.
- Fisher R. J., Gaynor E. R., Dahlberg S. et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med. 1993- 328: 1002−6.
- Gallagher C.J., Gregory W.M., Jones A.E. et al. // Follicular lymphoma: prognostic factors for response and survival. // J. Clin. Oncol., 1986, 4, 14 701 480.
- Gomez H, Hidalgo M, Casanova L. et al.// Risk factor for treatment — related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis.// J Clin. Oncol 1998−16:2065
- Greiner TC, Medeiros LJ, and Jaffe ES Non-Hodgkin's lymphoma. Cancer 1995−75:370−80
- Gribben J.G. // How 1 tread indolent lymphoma. // Blood, 2007, 11, 46 174 626.
- Grogan L., Corbally N., Dervan PA., Byrne A., Carney GN.// Comparable prognostic factors and survival in elderly patients with aggressive non
- Hodgkln’s lymphoma treated with standard-dose Adriamycin-based regimens// Ann. Oncol 1994−5-47
- Groves FD, Linet MS, Travis LB, t al. Cancer surveillance series: Non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 throught 1995. J Natl Cancer Inst 2000−92:1240−51
- Guillemini C.L., Lehmann W.L. Subsequent malignancies following treatment of advanced laryngeal cancer // Jahresveramml. Schweiz. Ges. Hed. Radiol. Abstr. 1992. Vol. 122, № 17. Suppl. 45. P. 36.
- Habermann TM, Weller EA, Morrison VA et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J. Clin. Oncol. 24 (19), 3121−3127 (2006)
- Hainsworth JD. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter Phase II trial. Semin. Oncol. 29 (1 Suppl. 2) 25−29 (2002)
- Hartge P., Devesa S.S., Fraumeni J.F. et al. // In: Cold Spring Harbor Laboratory Press, 1994, 423−453.
- Hiddemann W., Ann. One., 1999, 10 (sup. 3): abs. 016
- Hiddemann W. Proc ASCO 2004- 23: abs. 6501.
- Horning S.J., Rosenberg S.A. // The natural history of initially untreated low-grade non-Hodgkin's lymphomas. //N. Engl. J. Med., 1984, 311, 1471−1475
- Horning S.J. // Investigation of monoclonal antibody therapy with conventional and high-dose treatment: current clinical trials. // Semin Hematol., 2000, 37 (4), 27−33.
- Hoster E, Dreyling M, Klapper W et al.- German Low Grade Lymphoma Study Group (GLSG), European Mantle Cell Lymphoma Network. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Bloodl 11(2), 558−565 (2008)
- Howe HL, Wingo PA, Thun MJ, et al Annual report to the nation on the status of cancer (1973 throught 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 2001- 93:824−42.
- Inoyue SK, Peduzzi PN, Robison JT et al. Importance of functional measures in predicting mortality among older hospitalized patients // JAMA 1998−279:1187−1193.
- Isaacson P., Muller-Hermelink H., Piris M., et al. Pathology & genetics. Tumours of Haematopoietic and Lymphoid Tissues / Eds E Joffe,, H. Stein. Lyon: IARS Press, 2001.-P .157−160
- Jaffe ES, Harris NL, Stein H, et al., eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumors of
- Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer, 2001)
- Jemal A, Siegel R, Ward E et al. Cancer stastics, 2008. CA Cancer J. Clin. 58(2), 71−96 (2008)
- Jantunen E, Itala M, Juvonen E et al. Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin's lymphoma: a nation-wide analysis. Bone Marrow Transplant.37(4), 367−372 (2006).
- Kenedy BJ. Aging and cancer. J Clin Oncol 1988−6:1903−11
- Langer C.J., Manola J., Bernardo P. et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implication of Eastern Cooperative Oncology Group 5592, a randomized trial // Jnatl Cancer Inst 2002−94:173−181
- Leonard R.C.F., Hayward R.L., Prescott R.J. et al. // The identification of discrete prognostic groups in low-grade non-Hodgkin's lymphoma. // Ann. Oncl., 1991,2, 655−662.
- Lopez A et al.// Febrile Neutropenia in Lymphoma Patients is Associated with Substantial Resource use and Healthcare Costs in Clinical Practice in Spain// Blood 2006- 108:475b.Abstr 5512.
- Lossos IS, Czerwinski DK, Alizadeh AA et al. Prediction of survival in diffuse large B-cell lymphoma based on the expression of six genes. N.Engl.J.Med.350(18), 1828−1837 (2004)
- Maartens E, Hermans J, Kluin-Nelemans JC, et al. Elderly patients with non-Hodgkin's lymphoma: population-based results in The Netherlands. Ann Oncol 1998−9:1219−27.
- Maor MH, Velasquez WS, Fuller LM et al.//Stomach conservation in Stages IE and IIE gastric non-Hodgkin's lymphoma// J. Clin Oncolog 1990- 8: 266 271.
- Marcus R. et al. Blood 2003- 102: 28a (abs. 87)
- Marcus. R et al.//CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.//Blood 2005 105−1417−1423
- Mead G.M., Macbeth F.R., Ryall R.D.H. et al. // A report on a prospective trial of no initial therapy in patients with asymptomatic favourable prognosis non-Hodgkin's lymphoma. //Hematol. Oncol., 1984, 2, 179−188.
- Meyer RM. Browman GP, Samosh ML et al.//Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma.//J. Clin. Oncol. 1995−13:2386−93
- Montoto S., Lopez-Guillermo A., Altes A. et al. // Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients withfollicular lymphoma at first progression. // Ann. Oncol., 2004, 15, 14 841 489.
- Newell G, Krementz E, Robertz J. Multiple primary neoplasms in blacks compared to whites. Further cancer in patients with cancer of the digestive organs. J Natl Cancer Inst 1975- 54: 331−4.
- O’Brien M.E.R., Macbeth F.R., Ryall R.D.H. et al. // The natural history of low grade non-Hodgkin's lymphoma and the impact of no initial treatment policy on survival. // Q. J. Med., 1991, 80, 651−660.
- Osterborg A. International Workchop on Multiple Myeloma 5th, 1995.
- Pfreundschuh M, Trumper L, Kloess M. et al 2-weekly CHOP (CHOP-14): The new standart regimen for patients with Aggressive Non-Hodgkin's Lymphoma (NHL) >60 years of age. Proc. ASH 2001−3027 (abstr)).
- Pluda J.M., Venzon D.J., Tosato G. et al.// Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral thrapy // J. Clin. Oncol., 1993, vol. 11, 1099−1107
- Portlock C.S., Rosenberg S.A. // No initial therapy for stage III and IV non-Hodgkin's lymphomas of favorable histiligic types. // Ann. Intern. Med., 1979, 90, 10−13.
- Portlock C.S., Rosenberg S.A., Glatstein E. et al. // Treatment of advanced non-Hodgkin's lymphomas with favorable histologies: preliminary resalts of a prospective trial. // Blood, 1976, 47, 747−756.
- Reis L.A.G., Miller B.A., Hankey B.F. et al. // SEER: Cancer Statistics Review (1973−1991): Tables and Graphs. // National Cancer Institute. NIH Publication, 1994, 94, 2789.
- Reuben DB, Rubenstein LV, Hirsch SH et al. Value of functional status as predictor of mortality // Am J Med 1992−93:663−669.
- Rohatiner A. Z. Gregory W.M., Peterson B. et al. // Meta-analisis to evaluate the role of interferon in follicular lymphoma. // J. Clin. Oncol., 2005, 23, 2215−2223.
- Romaguera J.E., McLaughlin P., North 1. et al. // Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: A risk model. //J. Clin. Oncol., 1991, 9, 762−769.
- Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002−346:1937−47
- Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma Cancer Cell 2003−3:185−97.
- Rossini F, Mingozzi S, Pogliani EM. Et al. Resent Prog Med 1991−82:262
- Sano Т. Recent Results Cancer Res 2000- 156: 104−7.
- Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer // Ann Intern Med 1994−120:104−110
- Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that pf other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003−102:3871−9
- Schoenberg B. Multiple primary malignant neoplasms. The Connecticut experience, 1935−1964. Berlin-Heidelberg-New York: Springer-Verlag.- 1977- 173
- SEER Cancer Statistics Review, 1975−2005. Ries LAG, Melbert D., Kraphco M. Et al. (Eds). Nacional Cancer Institute, Bethesda, MD, USA (2008).
- Siu AL, Moshita L, Blaustein J. Comprehensive geriatric assessment in a day hospital // J Am Geriatr Soc 1994−42:1094−1099.
- Smith TJ., Khatcheressian J., Lyman G. H. et al., Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline Journal of Clinical Oncology, Vol 24, No 19 (July 1), 2006: pp. 3187−3205
- Solar — Celigny P., Cbastang C., Herrerat. et al. Age as the main prognostic factor in adult aggressive non-Hodgkin's lymphoma. Am. J. Med.- 1987- 83: 1075−9.1,
- Solar-Celigny P., Roy P., Colombat P. et al. // Follicular lymphoma international index. // Blood, 2004, 104, 1258−1265.
- Sonneveld P., de Ridder M., van der Lelie H. et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J. Clin. Oncol.- 1995- 13: 2530−39.
- Sonneveld P, Michiels J.J.// Full dose chemotherapy in elderly patients with non-Hodgcin's lymphoma: a feasibility study using a mitoxantrone containing regimen.//Br J Cancer 1990−62:105 108
- Staudt LM. Molecular diagnosis of the hematologic cancer. N Engl J Med 2003−348:1777−85 (review),
- Sutcliffe S., Gospodarowicz M. Localized extranodal lymphomas. In Keating A., Armitage A., Burnett J. Newland A eds.: Haematological Oncology, Cambridge, Cambridge Medical Reviews, 1992- pp 189−222
- The International Non -Hodgkkfs Lymphoma Prognostic Factors Project. A predictive model for aggressive Non Hodgkin’s Lymphoma. N. Engl. J. Med 1993- 329:987−94
- The Non-Hodgkin's Lymphoma Classification Project. A clinical trial of the International lymphoma Study Group clfssification of non-Hodgkin Lymphoma. Blood 1997−89:3909−18
- The Non-Hodgkin's Lymphoma Classification Project. Effect of age on the characteristics and clinical behavior of non- Hodgkin’s Lymphoma patients. Ann Oncol 1997- 8:973−8.
- Thieblemont C., Coffier В., Lymphoma in older patients. J.Clin. Oncol. 25(14), 1916−1923 (2008)
- Thieblemont C, Grossoeuvre A, Houot R. et al. Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann. Oncol. 19(4), 774−779 (2008).
- Thirlby RC.// Gastrointestinal lymphoma: a surgical perspective.// Oncology 1993- 7: 29−32.
- Tsavaris N, Kosmas C, Vadiaca M, Giannouli S et al. Pegylated liposomal doxorubicin in the CHOP regimen for older patients with aggressive (stages III/IV) non-Hodgkin's lymphoma. Anticancer Res. 2002 May-Jun- 22 (3): 1845−8.
- Unterhalt M., Herrmann R., Nahler V., et al., Blood, 1996- 86(10): A-1744, 439a.
- Van Sprjnsen DJ, Janssen-Heijnen ML., Breed WP., Coebergh JW.//Prevalence of comorbidity and its relation-ship to treatment among un-selected patients with Hodgkin"s disease and non-Hodgkin"s lymphoma.// Ann. Hematol 1999−78:315-
- Vose JM, Armitage JO, Weisenburger DD. The importance of age in survival in patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1986: 4: 295−305.
- Vose J.M., Armitage J.O. Weisenburger D.D. et al. J. clin. Oncol. 1988- 6:1838,
- Warren S, Ehrenreich T. Multiple primary malignant tumors, a survey of the literature and statistical study. Am J Cancer 1932- 16: 1353.11
- Watanabe S. Multiple primary neoplasms: role of autopsy, selected sited with emphasys on Japan. Influense Tumor Dev. Host. (Dordrecht etc.). 1989- 35−9.
- Wildiers H, Highley MS, Ernst A et al. Pharmacology of anticancer drugs in the elderly population // Clin. Pharmacokin 2003−42(14):1213−1242-
- Wiseman LR, Spencer CM. Dexrazoxane: a review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy // Drugs 1998−56:385103
- Wood DP, Montie JE, Edson PJ, Levin US. Identification of transitional cell carcinoma of the prostate in bladder cancer patients: a prospective stuidy. J Urol 1989−142(l):83−5.
- Wotherspoon A.C., Doglioni C., Isaacson P.G.// Low-grade gastric B-cell lymphoma of mucosa-associated lymphoid tissue (MALT): an ultrastuctual study.// Histopathology 1992- 20: 29.
- Wright G, TanB, Rosenvald A, Hurt E.H., Wiestner A, Staudt L.M. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B-cell lymphoma. Proc. Natl Acad. Sci. USA 100(17), 9991−9996 (2003).
- Zinzani PL, Martelli M, Storti S, Musso M, Cantonetti M, Leone G et al. Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma 1995- 19: 329−335.
- Zinzani PL, Pavole E, Storti S, et al// Randomized Trial with or without Granulocyte Colony-Stimulating Factor as Adjunct to induction VNCOP-B Treatment of Elderly High — Grade non-Hodgkin's lymphoma.//Blood 1997−89:3974